2160.HK实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (28 Jun 2024 @ 16:08):
Our systems believe the stock currently is undervalued by 0.03% compare to its pairs and should correct upwards.

Stats
今日成交量	7.10M
平均成交量	4.81M
市值	2.00B
EPS	HKD-0.0618 ( Q4 \| 2023-12-31 )
下一个收益日期	( HKD0 ) 2024-08-27
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-3.77 (Sector) 14.27 (Industry) 0
ATR14	HKD0.00500 (0.60%)

0853.HK -4.70%

1612.HK -1.18%

1696.HK 1.69%

1763.HK -2.33%

1789.HK -0.92%

1858.HK -0.92%

2160.HK 0.00%

2170.HK -3.59%

2190.HK 1.73%

2216.HK 1.69%

2235.HK -0.26%

2252.HK -4.24%

2393.HK 2.27%

2500.HK -0.71%

6118.HK -2.86%

6609.HK 0.00%

6669.HK 3.64%

9996.HK -5.00%

相关性 (AI algo v.1.1b): Undervalued: 0.03% HKD0.830 paired level. (算法实时跟踪最相关股票的变化并提供即时更新)

音量相关性

長: -0.21 (neutral)

短: -1.00 (very strong negative)

Signal:(31.778) Neutral

MicroPort CardioFlow 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

MicroPort CardioFlow 相关性 - 货币/商品

0.24
( neutral )

0.11
( neutral )

0.00
( neutral )

0.17
( neutral )

MicroPort CardioFlow 财务报表

Annual	2023
营收:	HKD336.22M
毛利润:	HKD229.93M (68.39 %)
EPS:	HKD-0.200

FY	2023
营收:	HKD336.22M
毛利润:	HKD229.93M (68.39 %)
EPS:	HKD-0.200

FY	2022
营收:	HKD251.03M
毛利润:	HKD162.13M (64.59 %)
EPS:	HKD-0.190

FY	2021
营收:	HKD200.81M
毛利润:	HKD118.70M (59.11 %)
EPS:	HKD-0.0775

Financial Reports:

No articles found.

MicroPort CardioFlow Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

MicroPort CardioFlow

MicroPort CardioFlow Medtech Corporation, a medical device company, researches, develops, and commercializes transcatheter and surgical solutions for structural heart diseases in the People's Republic of China. It offers Vitaflow Aortic Valve System, Alwide Balloon Catheter, and Alpass Introducer Set to target aortic, mitral, tricuspid, and surgical valves, as well as procedural accessories. The company was founded in 2010 and is headquartered in Shanghai, China.